Replacing the Missing Orexin: Narcolepsy Gets a Drug That Treats the Cause, and Maybe a GLP-1 for the Brain
The FDA has approved the first orexin agonist, which replaces the orexin that type 1 narcolepsy patients lack instead of merely managing symptoms; it could become a ‘GLP-1 for the brain’. Separately, brain organoids have survived past five years for the first time, opening up research into late-onset brain disease.
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
Sleeping through the day and awake all night are one disease
Narcolepsy comes in two forms, type 1 and type 2, and the core of it is excessive daytime sleepiness: patients can drop into brief periods of deep sleep with no warning at all, while at night they are instead sleepless, and they may also have nightmares, sleep paralysis and hallucinations. Type 1 patients suddenly lose muscle tone under strong emotion such as hard laughter — that is cataplexy. The existing drugs handle only symptoms: stimulants during the day, sleeping pills at night, neither of them touching the cause.
— MarStimulants plus sleeping pills were never treating the cause
Treatment until now has only managed symptoms: stimulants to hold wakefulness through the day, sleeping pills to help with sleep at night. The host offers the example of a friend of theirs, who fell asleep during the brief gap of waiting at a red light — that became the clue that led to diagnosis. The drug the FDA has now approved is the first to target the underlying cause of narcolepsy, and diagnosed patients in the US can obtain it on prescription.
— NickWhat type 1 lacks is orexin; type 2 runs on something else
Most scientists believe the root cause in type 1 is that the brain lacks a peptide called orexin, which is responsible for regulating the sleep-wake cycle. The new drug is an orexin agonist — in essence it mimics what orexin does, replacing the missing signal. The discussion draws the analogy to GLP-1: GLP-1 agonists mimic a gut hormone that regulates satiety, whereas this drug mimics a missing molecule inside the brain. Type 2 has a different mechanism and may involve other neurons and pathways as well, so orexin is not the only root cause.
— MarOn the drug, patients' sleep cycles are indistinguishable from normal
In the clinical trials the drug was highly effective; a patient interviewed said their life had been completely transformed, and a scientist involved in the research said that once patients are on the drug their sleep cycles are essentially indistinguishable from those of a ‘normal’ person. Millions of patients stand to benefit. The key thing is that it could become a ‘GLP-1 for the brain’: GLP-1 expanded from type 2 diabetes into weight loss, and this orexin agonist may likewise act on other neural pathways — researchers want to try it on ADHD symptoms and on the fatigue associated with multiple sclerosis and Parkinson's disease.
— MarBrain organoids can live five years and develop on a human timeline
By optimizing culture conditions, changing the medium partway through and continuously promoting new neurons, researchers kept brain organoids alive for more than five years, where previous organoids died within months. They follow a developmental trajectory similar to the human brain: from 15 days to 2 months the gene expression looks like a first-trimester fetus, at 3 to 6 months like the second trimester, and past 12 months like an infant brain. These are long-term changes nobody could see before.
— MarNeurons remember their own age, so you can bank them by age
Many brain diseases occur late in development — schizophrenia, for example — and existing organoids do not survive to that stage. The five-year organoid lets researchers observe this kind of late-onset disease. More important still, neurons appear to ‘remember their own age’: mix old cells together with new ones, and the old neurons still behave according to their older developmental stage. That makes it possible to bank them by age, freeze them and draw on them at any time, creating libraries of neurons at different developmental stages. The team's next step is to add sensory input such as vision and smell; if signs of consciousness were to appear in future, it would provoke an ethical debate.
— MarIn their own words · checked verbatim
it's characterized by excessive daytime sleepiness so you have a lot of trouble staying awake during the day.
Mar0:00
Exactly, I have a friend who has it actually, and she described, you know, one of the reasons that she ended up getting diagnosed was because.She like found herself falling asleep at traffic lights for tiny little increments of time
Nick1:36
With this drug, it's an orexin agonist, so it mimics the function of orexin in your brain, which is missing from people with type 1 and narcolepsy.
Mar2:38
Many neuroscientists hope and potentially believe that this drug, this orexin agonist.Could potentially be like a GLP1 for the brain where it could maybe also impact other neurological pathways.
Mar4:28
the thing that researchers are hoping that they'll be able to do is allow us to look at conditions.That occur later on in development.
Mar9:53
the brain cells, they remembered what stage they were in, they remembered how old they were
Mar11:03
Figures
| Narcolepsy subtypes | type 1 and type 2 | 0:00 |
| People affected | millions worldwide | 4:28 |
| Longest brain organoid survival | more than five years | 9:53 |
| Developmental benchmark | past 12 months, gene expression resembles an infant brain | 9:53 |
Glossary
- narcolepsy
- A sleep disorder whose main feature is excessive daytime sleepiness, divided into type 1 and type 2.
- cataplexy
- A sudden loss of muscle tone under strong emotion; the hallmark of type 1 narcolepsy.
- orexin
- A neuropeptide secreted by the hypothalamus that regulates the sleep-wake cycle; type 1 patients lack it.
- orexin agonist
- A drug that replaces the missing signal by mimicking orexin's function — the mechanism of the newly approved narcolepsy drug.
- brain organoid
- A simplified, miniature three-dimensional brain structure grown from stem cells; not conscious, and usable for studying development and disease.
- GLP1
- Glucagon-like peptide-1, a gut hormone whose agonists are used for diabetes and weight loss; the analogy here is a ‘GLP-1 for the brain’.
How to listen
Researchers and investors following sleep medicine and neuro drug pipelines; engineers and founders working on stem-cell models or organoid platforms; sleep clinicians.
The symptom primer (0:00-1:36) can be fast-forwarded — go straight to the mechanism at 2:38 and the applications after 9:53.